BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28275168)

  • 1. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
    Tang C; Sherman SI; Price M; Weng J; Davis SE; Hong DS; Yao JC; Buzdar A; Wilding G; Lee JJ
    Clin Cancer Res; 2017 Mar; 23(6):1414-1421. PubMed ID: 28275168
    [No Abstract]   [Full Text] [Related]  

  • 2. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual.
    Tang C; Hess KR; Sanders D; Davis SE; Buzdar AU; Kurzrock R; Lee JJ; Meric-Bernstam F; Hong DS
    Clin Cancer Res; 2017 Mar; 23(6):1407-1413. PubMed ID: 27852698
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.
    Massett HA; Mishkin G; Rubinstein L; Ivy SP; Denicoff A; Godwin E; DiPiazza K; Bolognese J; Zwiebel JA; Abrams JS
    Clin Cancer Res; 2016 Nov; 22(22):5408-5416. PubMed ID: 27401246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.
    Gerber DE; Lakoduk AM; Priddy LL; Yan J; Xie XJ
    Oncologist; 2015 Jun; 20(6):674-82. PubMed ID: 26018661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
    Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2011 Apr; 17(7):1947-55. PubMed ID: 21447723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
    Korn EL; Freidlin B; Mooney M; Abrams JS
    J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.
    Peterson JS; Plana D; Bitterman DS; Johnson SB; Aerts HJWL; Kann BH
    Cancer Med; 2023 Feb; 12(4):4715-4724. PubMed ID: 36398619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights From Building a New National Cancer Institute Community Oncology Research Program Site.
    Saphner T; Thompson MA; Planton S; Singh M; Glandt N; Robinson L; DeBartolo J
    WMJ; 2016 Aug; 115(4):191-5. PubMed ID: 29099156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
    Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual.
    Mileham KF; Kim ES
    Clin Cancer Res; 2016 Nov; 22(22):5397-5399. PubMed ID: 27601589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.
    Zaren HA; Nair S; Go RS; Enos RA; Lanier KS; Thompson MA; Zhao J; Fleming DL; Leighton JC; Gribbin TE; Bryant DM; Carrigan A; Corpening JC; Csapo KA; Dimond EP; Ellison C; Gonzalez MM; Harr JL; Wilkinson K; Denicoff AM
    J Oncol Pract; 2013 Mar; 9(2):e55-61. PubMed ID: 23814525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
    Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
    Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.
    Paul K; Sathianathen N; Dahm P; Le C; Konety BR
    J Urol; 2019 Aug; 202(2):385-391. PubMed ID: 31074679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
    Baquet CR; Ellison GL; Mishra SI
    J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial accrual among new cancer patients at a community-based cancer center.
    Go RS; Frisby KA; Lee JA; Mathiason MA; Meyer CM; Ostern JL; Walther SM; Schroeder JE; Meyer LA; Umberger KE
    Cancer; 2006 Jan; 106(2):426-33. PubMed ID: 16353206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity.
    Hirsch BR; Locke SC; Abernethy AP
    J Oncol Pract; 2016 Apr; 12(4):e350-8. PubMed ID: 27026649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
    Le-Rademacher J; Mohile S; Unger J; Hudson MF; Foster J; Lichtman S; Perlmutter J; Dotan E; Extermann M; Dodd K; Tew W; Klepin H; Wildes TM; Sedrak MS; Jatoi A; Little RF
    J Natl Cancer Inst Monogr; 2022 Dec; 2022(60):135-141. PubMed ID: 36519818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP; Lilenbaum RC
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.